DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Jun 2

PMID 31151158

Citations 30

Authors

Louise Katrine Larsen

Guro Elisabeth Lind

Per Guldberg

Christina Dahl

Affiliations

Soon will be listed here.

Abstract

Changes in DNA methylation have been causally linked with cancer and provide promising biomarkers for detection in biological fluids such as blood, urine, and saliva. The field has been fueled by genome-wide characterization of DNA methylation across cancer types as well as new technologies for sensitive detection of aberrantly methylated DNA molecules. For urological cancers, urine is in many situations the preferred "liquid biopsy" source because it contains exfoliated tumor cells and cell-free tumor DNA and can be obtained easily, noninvasively, and repeatedly. Here, we review recent advances made in the development of DNA-methylation-based biomarkers for detection of bladder, prostate, renal, and upper urinary tract cancers, with an emphasis on the performance characteristics of biomarkers in urine. For most biomarkers evaluated in independent studies, there was great variability in sensitivity and specificity. We discuss issues that impact the outcome of DNA-methylation-based detection of urological cancer and account for the great variability in performance, including genomic location of biomarkers, source of DNA, and technical issues related to the detection of rare aberrantly methylated DNA molecules. Finally, we discuss issues that remain to be addressed to fully exploit the potential of DNA-methylation-based biomarkers in the clinic, including the need for prospective trials and careful selection of control groups.

Citing Articles

Urinary DNA-methylation and protein biomarkers identify urothelial carcinoma among other genitourinary diseases and cancer-free individuals.

Lang K, Kohler C, Wichert K, Deix T, Bartsch G, Sommer G J Transl Med. 2024; 22(1):1061.

PMID: 39587670 PMC: 11590282. DOI: 10.1186/s12967-024-05844-x.

Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials.

Huang F, Di X, Bai M Front Bioeng Biotechnol. 2024; 12:1458362.

PMID: 39295845 PMC: 11408225. DOI: 10.3389/fbioe.2024.1458362.

Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target.

Wang Y, Wang J, Zhang L, He J, Ji B, Wang J J Cell Mol Med. 2024; 28(7):1-20.

PMID: 38506098 PMC: 10951887. DOI: 10.1111/jcmm.18213.

Use of Multiple Machine Learning Approaches for Selecting Urothelial Cancer-Specific DNA Methylation Biomarkers in Urine.

Kohler C, Schork K, Turewicz M, Eisenacher M, Roghmann F, Noldus J Int J Mol Sci. 2024; 25(2).

PMID: 38255812 PMC: 10815677. DOI: 10.3390/ijms25020738.

Biomarkers in renal cell carcinoma and their targeted therapies: a review.

Gupta S, Kanwar S Explor Target Antitumor Ther. 2023; 4(5):941-961.

PMID: 37970211 PMC: 10645469. DOI: 10.37349/etat.2023.00175.

References

Eads C, Danenberg K, Kawakami K, Saltz L, Blake C, Shibata D . MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000; 28(8):E32. PMC: 102836. DOI: 10.1093/nar/28.8.e32. View

Grunau C, Clark S, Rosenthal A . Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 2001; 29(13):E65-5. PMC: 55789. DOI: 10.1093/nar/29.13.e65. View

Goessl C, Muller M, Heicappell R, Krause H, Straub B, Schrader M . DNA-based detection of prostate cancer in urine after prostatic massage. Urology. 2001; 58(3):335-8. DOI: 10.1016/s0090-4295(01)01268-7. View

Goessl C, Muller M, Heicappell R, Krause H, Miller K . DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci. 2001; 945:51-8. DOI: 10.1111/j.1749-6632.2001.tb03863.x. View

Chan M, Chan L, Tang N, Tong J, Lo K, Lee T . Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002; 8(2):464-70. View

Deng G, Peng E, Gum J, Terdiman J, Sleisenger M, Kim Y . Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br J Cancer. 2002; 86(4):574-9. PMC: 2375277. DOI: 10.1038/sj.bjc.6600148. View

Jeronimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C . Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002; 60(6):1131-5. DOI: 10.1016/s0090-4295(02)01949-0. View

Chan M, Chan L, Tang N, Lo K, Tong J, Chan A . Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer. 2003; 104(5):611-6. DOI: 10.1002/ijc.10971. View

Laird P . The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003; 3(4):253-66. DOI: 10.1038/nrc1045. View

10.

Gonzalgo M, Pavlovich C, Lee S, Nelson W . Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res. 2003; 9(7):2673-7. View

11.

Dahl C, Guldberg P . DNA methylation analysis techniques. Biogerontology. 2003; 4(4):233-50. DOI: 10.1023/a:1025103319328. View

12.

Battagli C, Uzzo R, Dulaimi E, de Caceres I, Krassenstein R, Al-Saleem T . Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 2003; 63(24):8695-9. View

13.

Sathyanarayana U, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A . Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res. 2004; 64(4):1425-30. DOI: 10.1158/0008-5472.can-03-0701. View

14.

Dulaimi E, Uzzo R, Greenberg R, Al-Saleem T, Cairns P . Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res. 2004; 10(6):1887-93. DOI: 10.1158/1078-0432.ccr-03-0127. View

15.

Hoque M, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra W . Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004; 64(15):5511-7. DOI: 10.1158/0008-5472.CAN-04-0799. View

16.

Friedrich M, Weisenberger D, Cheng J, Chandrasoma S, Siegmund K, Gonzalgo M . Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res. 2004; 10(22):7457-65. DOI: 10.1158/1078-0432.CCR-04-0930. View

17.

Nygren A, Ameziane N, Duarte H, Vijzelaar R, Waisfisz Q, Hess C . Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005; 33(14):e128. PMC: 1187824. DOI: 10.1093/nar/gni127. View

18.

Hoque M, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W . Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005; 23(27):6569-75. DOI: 10.1200/JCO.2005.07.009. View

19.

Yates D, Rehman I, Meuth M, Cross S, Hamdy F, Catto J . Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene. 2005; 25(13):1984-8. DOI: 10.1038/sj.onc.1209209. View

20.

Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H . Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res. 2006; 12(7 Pt 1):2109-16. DOI: 10.1158/1078-0432.CCR-05-2468. View